Informations

Breast cancer is one of the most common malignant tumors in women and is often referred to as the “pink killer,” posing a serious threat to women’s health. The World Health Organization has designated October as “World Breast Cancer Awareness Month” (also known as Pink Ribbon Month) to raise women’s awareness of breast cancer prevention.…

Breast cancer is one of the most common malignant tumors in women and is often referred to as the “pink killer,” posing a serious threat to women’s health. The World Health Organization has designated October as “World Breast Cancer Awareness Month” (also known as Pink Ribbon Month) to raise women’s awareness of breast cancer prevention.…

Oncology Frontier: Please share the key findings of the NSABP B-59/GBG-96-GeparDouze study. In particular, what are the highlights regarding the efficacy and safety of atezolizumab when added to neoadjuvant chemotherapy…

Oncology Frontier：You introduced “Early Breast Cancer Updates” in Year in Review session. Please review the lecture and tell us about the research progress in the field of early breast cancer…

Oncology Frontier：Could you tell us about the original intention of conducting this URCC 16070 phase III randomized controlled trial? Why choose olanzapine and prochlorperazine as agents for nausea caused by…

Oncology Frontier: You and Professor Zhimin Shao jointly presided over the General Session 2 of this conference. As the moderator of this session, could you please give us an overview…

A pivotal study published on April 23, 2024, in the Journal of Clinical Oncology explored the efficacy of Datopotamab Deruxtecan (Dato-DXd) in advanced HR+/HER2– and triple-negative breast cancer (TNBC). Led…